VG2062
/ CNBG-Virogin Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 04, 2025
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors
(clinicaltrials.gov)
- P1 | N=30 | Not yet recruiting | Sponsor: Shanghai Virogin Biotech Co., Ltd.
New P1 trial • Solid Tumor
1 to 1
Of
1
Go to page
1